Related Experiment Video
Updated: Apr 6, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
7.5K
Current treatment for chronic hepatitis B in Japan
Waka Ohishi1,2, Kazuaki Chayama3
1Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
Clinical Journal of Gastroenterology
|July 21, 2015
Summary
Updated Japanese guidelines standardize chronic hepatitis B diagnosis and treatment. They define patient eligibility based on ALT levels, HBV DNA, and HBeAg status, guiding therapy choices for diverse patient groups.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Background:
- Chronic hepatitis B (CHB) requires standardized diagnostic and treatment protocols.
- Advancements in antiviral therapies necessitate updated clinical guidelines.
- The Japanese Ministry of Health, Labor and Welfare (MHLW) initiated a project to standardize viral liver disease treatment.
Purpose of the Study:
- To present updated treatment guidelines for chronic hepatitis B in Japan.
- To standardize the diagnosis, treatment, and management of CHB.
- To provide a framework for clinicians managing diverse CHB patient populations.
Main Methods:
- Formulation of guidelines by an MHLW-led research team.
- Inclusion of criteria for treatment initiation based on ALT, HBV DNA, and HBeAg status.
- Stratification of treatment recommendations by age, HBeAg status, and viral load.
Main Results:
- Guidelines recommend treatment for CHB patients with specific ALT, HBV DNA, and HBeAg thresholds.
- Treatment strategies are tailored for different age groups (young vs. middle-aged/elderly) and HBeAg status.
- Specific recommendations are provided for switching from lamivudine to entecavir based on treatment duration and viral load.
Conclusions:
- The updated guidelines offer a comprehensive approach to CHB management.
- Consideration of patient age, ALT, HBeAg, HBV DNA, and liver severity is crucial for effective treatment.
- These guidelines support the understanding and implementation of evolving CHB diagnosis and treatment strategies.
More Related Videos
Related Concept Videos
01:25Hepatitis
42
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
01:28Pulmonary Tuberculosis V
888
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
888
01:29Chronic Pancreatitis II: Collaborative Care
496
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
496
01:30Inhibitors of Viral Protein Synthesis
32
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
764
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.2K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.2K